research use only

GW5074 Raf inhibitor

Cat.No.S2872

GW5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms is noted. This compound inhibits LK-induced apoptosis.
GW5074 Raf inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 520.94

Jump to

Quality Control

Batch: S287201 DMSO]104 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.8%
99.8

Solubility

In vitro
Batch:

DMSO : 104 mg/mL (199.63 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 520.94 Formula

C15H8Br2INO2

Storage (From the date of receipt)
CAS No. 220904-83-6 Download SDF Storage of Stock Solutions

Synonyms N/A Smiles C1=CC2=C(C=C1I)C(=CC3=CC(=C(C(=C3)Br)O)Br)C(=O)N2

Mechanism of Action

Targets/IC50/Ki
C-Raf
(Cell-free assay)
9 nM
In vitro

GW5074 is a potent and specific inhibitor of c-Raf with IC50 of 9 nM and has no effect of MKK6, MKK7, p38 MAP kinase and cdks in vitro. However, treatment of neuronal cultures with this compound permits accumulation of activating modifications on c-Raf and also B-Raf. The inhibition of LK-induced apoptosis by this inhibitor in cerebellar granule neurons is not MEK-ERK-dependent. This chemical delays down-regulation of Akt activity but inhibits apoptosis by an Akt-independent mechanism. It affects Ras, nuclear factor-kappa B and c-jun. This compound inhibits cell death caused by neurotoxins in granule cells and other neuronal types.

Kinase Assay
Affinity determination
In general, in vitro kinase assays are performed using purified kinase and synthetic substrates under standard conditions using the Kinase Profiling service of Upstate Biotechnology. Briefly, for each assay 5–10 mU of purified kinase is used. For GSK3β, cdk1, cdk2, cdk3, cdk5, the kinase is incubated with 1 μM GW5074 in a buffer containing 8 mM MOPS, pH 7.2, 0.2 mM EDTA, 10 mM magnesium acetate and [c- 33P-ATP] for 40 min at room temperature. Kinase activity is quantified by measuring 33P incorporation by spotting an aliquot on P30 filters, washing in 50 mM phosphoric acid and scintillation counting. The buffer composition for c-Raf, JNK1, JNK2, JNK3, MEK1, MKK6, MKK7 is 50 mM Tris pH 7.5, 0.1 mM EGTA, 10 mM magnesium acetate and [c- 33P-ATP]. The peptide substrates used are as follows: For c-Raf, 0.66 mg/mL MBP; for cdks, 0.1 mg/mL histone H1; for JNKs, 3 μM ATF2; for MEK1, 1 μM MAPK2; for MKK6, 1 μM of SAPK2a and for MKK7, 2 μM JNK1α.
In vivo

GW5074 is protective in an in vivo experimental model of Huntington’s disease. This compound (5 mg/Kg) completely prevented extensive bilateral striatal lesions induced by 3-NP in mice.  It suppresses sidestream smoke-induced airway hyperresponsiveness in mice.

References

Applications

Methods Biomarkers Images PMID
Western blot p-Raf-1 / Raf-1 / p-c-Jun / c-Junc / c-Fos / P-gp
S2872-WB1
28212576

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map